

Index

A

- Abiraterone acetate, 254–256, 263, 267–268, 271, 317
- a/b* ratio, 130, 148
- Active surveillance, 33, 34, 51, 52, 62, 85–90, 113, 192, 204, 205, 304, 330–332
- Adjuvant radiotherapy, 173–185, 291
- ADT. *See* Androgen deprivation therapy (ADT)
- Age, 2, 3, 5, 7–9, 15, 17, 23, 27–32, 40, 43–44, 59–62, 70, 72, 74, 86–90, 97, 100, 121–123, 138, 166, 167, 177, 200, 203, 205, 214, 226, 229, 232, 269, 285, 289, 290, 300–303, 308, 314, 317, 328–330, 334
- 5-Alpha reductase inhibitors (5-ARIs), 9, 19–22, 59, 252, 314
- Alpha-blocker, 118, 123
- Anatomy, prostate, 39–44, 52, 98
- Androgen ablation therapy, 114
- Androgen deprivation
 - animal studies, 158
 - objective, 158
 - randomized trials, 158, 164, 166, 167
 - side effects, 158, 162, 167
- Androgen deprivation therapy (ADT), 19, 22, 74, 121, 122, 130, 131, 134, 136–139, 157–168, 177, 181, 185, 231–234, 243–247, 251–253, 263, 286–289, 305–307, 309–314, 316, 330
- Androgen receptor (AR), 9–10, 19, 22, 43, 47, 75, 164, 240, 242, 243, 251–258, 262, 266, 268, 316, 317
- Annexin A3 (ANXA3), 75–76
- Antiandrogens, 44, 240–243, 246, 247, 253, 330
- Antiandrogen withdrawal syndrome, 253, 254
- Antibiotic prophylaxis, 27, 117
- AR. *See* Androgen receptor (AR)
- 5-ARIs. *See* 5-Alpha reductase inhibitors (5-ARIs)
- ARO trial, 174, 175

B

- Bevacizumab, 269, 293
- Biomarkers, 33–34, 55–64, 72, 74–76, 80, 257–258, 271, 285, 293–294, 302, 329, 331, 334
- Blood markers, 56, 59–61, 71–74, 328
- Bounce, 124, 136–137

C

- CAB. *See* Combined androgen blockade (CAB)
- Cabazitaxel, 262, 271, 316, 318
- Cabozantinib, 266, 269
- Calcitriol, 270
- Cardiac disease, 167
- Charlson score, 32, 70, 82
- Chemoprevention, 13–23
- Choice of primary treatment, 328, 332–333
- Choline PET-CT, 125, 180, 314
- Circulating tumor cells (CTCs), 61, 63, 138, 139, 146, 258, 267, 268, 270–271
- Clinical target volume (CTV), 129, 132, 135, 138, 139, 147, 158, 166, 176, 182
- Clinicopathological staging, 48–50
- Combined androgen blockade (CAB), 164, 243, 310, 314, 330
- Combined treatment, Combination with EBRT, 113, 116, 120, 122, 123, 136, 159–163, 167, 244, 245, 284, 288, 306
- Complications, 96–98, 109, 206, 216–218, 318
- COX-2 inhibitors, 14–15
- Cryotherapy
 - complications, 216–218
 - cryobiology, 213–214
 - indications, 214–215
 - oncological outcomes, 218–221
 - procedure, 213–216
- CTCs. *See* Circulating tumor cells (CTCs)
- CT/MRI fusion, 147, 148, 303, 309
- CTV. *See* Clinical target volume (CTV)
- CYP17. *See* Cytochrome P450-17 (CYP17)
- Cytochrome P450-17 (CYP17), 252, 254–256, 266–268, 317

D

- D'Amico classification, 70, 77, 149, 234
- Denosumab, 246, 270, 271, 318, 333
- DES. *See* Diethyl stilbestrol (DES)
- DHT. *See* Dihydrotestosterone (DHT)
- Diet, 5, 9–10, 14, 15, 17–19, 22, 96, 117, 167
 - selenium, 9, 10, 15–16
 - vitamin E, 9, 10, 15–17
- Diethyl stilbestrol (DES), 159, 241–242, 246, 253, 309

Dihydrotestosterone (DHT), 1, 9, 19, 240, 252
 Docetaxel, 166, 207, 251, 254–256, 261–263, 265–271,
 316–318
 Dose
 constraints, 134–136
 escalation, 129, 130, 143–146, 151, 164–168,
 207, 256, 306, 307
 Dose of 90% of the prostate (D90), 118–120, 122,
 123, 136

E

Early Prostate Cancer Antigen 2 (EPCA-2), 73, 74
 EAU guidelines. *See* European Association
 of Urology (EAU) guidelines
 Endocrine treatment, 162, 306, 328–332
 Endopelvic fascia, 41, 95
 EPCA-2. *See* Early Prostate Cancer
 Antigen 2 (EPCA-2)
 Epidemiology, 1–10, 16–17, 167, 300, 312
 ERG. *See* Estrogen-regulated gene (ERG)
 ERSPC trial. *See* European Randomized Study of
 Screening for Prostate Cancer (ERSPC) trial
 Estramustine, 166, 254, 317
 ESTRO/EAU/EORTC recommendations, 115
 Estrogen-regulated gene (ERG), 47, 57, 62–63,
 75–76, 258, 268
 Ethnicity, 8, 9, 23, 60, 70
 Europa Uomo, 328, 333–334
 European Association of Urology (EAU)
 guidelines, 77, 215, 247, 299–318
 European Organization on Treatment and Research
 of Cancer (EORTC) trials, 159, 174,
 176, 178, 184, 285, 286, 290, 304
 EORTC 22863, 159, 160, 163, 244, 284
 EORTC 22961, 160, 163, 290, 306
 EORTC 22911, 174
 European Randomized Study of Screening for
 Prostate Cancer (ERSPC) trial, 26, 29,
 74, 203–204, 300, 332

F

Functional results, 94, 96–100

G

GEC/ESTRO-EAU recommendations, 121, 131
 GEC-ESTRO guidelines, 115
 Genitourinary tumor group (GETUG) trials
 GETUG 01, 166, 307
 GETUG 12, 166
 GETUG 14, 165
 GETUG trials. *See* Genitourinary tumor group
 (GETUG) trials
 Gonadotropin-releasing hormone (GnRH)
 antagonists, 242, 244
 Gothenburg trial, 29

H

Harms, 30, 86
 HE3235, 256
 High grade prostatic intraepithelial neoplasia
 (HGPIN), 19, 20, 23, 42, 44–45, 302
 High-intensity focused ultrasound (HIFU), 113,
 125, 139, 191–209, 215, 225, 226, 229,
 233, 234, 308, 314, 315
 Hypofractionated radiotherapy, 148, 150

I

IAD. *See* Intermittent androgen deprivation
 therapy (IAD)
 IGRT. *See* Image-guided radio-therapy (IGRT)
 IIEF. *See* International index of erectile function (IIEF)
 Image-guided radio-therapy (IGRT), 146–148, 151,
 164, 183, 185
 IMRT. *See* Intensity modulated radiation therapy (IMRT)
 Incidence, 1–5
 Individual screening, 31–34
 Indolent tumour, 56, 86, 329
 Innovative drugs and technology, 328, 332–333
 Intensity modulated radiation therapy (IMRT), 7, 125,
 130, 143–151, 164–166, 168, 176, 181–183, 185,
 306–308
 Intermittent androgen deprivation therapy
 (IAD), 231, 234, 243, 309–311, 313, 314
 International index of erectile function
 (IIEF), 70, 81–82, 98, 109, 138–139, 201
 International Prostate Symptom Score (IPSS), 19, 70,
 81, 114, 115, 123, 204, 307, 308
 Interval cancers, 30–31
 Intraoperative planning, 117, 122, 123, 131, 132
 Ipilimumab, 264–266
 Isoflavones, 17–18

K

Kallikrein, 4, 33, 59–61, 74
 Ketoconazole, 253, 254, 261, 267–268
 Ki-67, 57–58, 63

L

LHRH analogues. *See* Luteinizing hormone–releasing
 hormone (LHRH) analogues
 Lifetime risk, 25, 51, 329
 Localized prostate cancer (PCa), 3, 15, 57, 58, 69–70,
 73–74, 87, 89, 93, 94, 98, 100, 140, 157–168,
 192, 200, 201, 213, 215, 217, 219, 293, 306, 307,
 331
 Loose seeds, 118, 119, 122
 Low risk prostate cancer, 114, 192, 209
 Luteinizing hormone–releasing hormone (LHRH) ana-
 logues, 159, 164, 231, 234, 241–243, 246, 253,
 257, 309–310, 316
 Lycopene, 9, 10, 18

M

Magnetic resonance imaging (MRI), 51, 52, 71, 77–80, 86, 89, 90, 94, 114, 116, 119, 120, 122, 124, 125, 139, 147, 148, 176, 179, 182, 193–198, 203–205, 207–209, 226, 228, 229, 292, 303, 309, 318
 MDV 3100, 252, 255–258, 266, 268, 316, 317
 Mick applicator, 117
 Micro-RNA, 55, 61, 63
 Mortality, 5–7, 17, 28–30, 86–88, 99, 121, 122, 159, 162–164, 167, 227, 244, 245, 285, 301, 306, 328, 331, 333
 MRI. *See* Magnetic resonance imaging (MRI)
 MRI-guided HIFU, 207–208

N

Nerve-sparing, 93–100, 110, 184, 305, 306
 Neuroendocrine, 43, 46–47, 58–59, 240
 Nomograms, 32–34, 51, 62, 71, 72, 99, 220–221, 228, 269, 305

O

Open radical prostatectomy, 93–100, 106, 217
 Orchiectomy, 241, 243
 Organs at risk, 130, 132, 134, 135, 143, 144, 307
 Osteoporosis, 167, 243, 246
 Overdiagnosis, 25, 26, 30, 32, 34, 52, 85, 86, 89, 221, 330
 Overtreatment, 22, 25, 30, 52, 56, 86, 89–90, 185, 221, 291, 304, 329–331

P

Palladium-103, 115, 120
 Palliative therapy, 318
 PCa. *See* Prostate cancer (PCa)
 PCA3. *See* Prostate cancer gene 3 (PCA3)
 Pelvis irradiation, 138, 145
 Phenotype, 43, 58–59, 75, 76, 266
 PHI. *See* Prostate health index (PHI)
 PLCO trial. *See* Prostate, lung, colorectal, and ovarian (PLCO) trial
 Polyphenols, 17–19
 Postplanning, 119–120
 Preplanning, 115, 117, 131
 Prevalence
 Europe, 1–2, 8
 USA, 7–8
 Primary care treatment, 200–201, 203–205
 Prostate cancer gene 3 (PCA3), 33, 61–63, 71, 74–76, 302
 Prostate health index (PHI), 72, 73
 Prostate, lung, colorectal, and ovarian (PLCO) trial, 28–31, 300–301
 Prostate-specific antigen (PSA), 4, 13, 25, 43, 56, 69, 85, 94, 114, 130, 145, 158, 173, 195, 215, 225, 245, 251, 263, 289, 300, 327

density (PSA d), 27, 60, 71, 301
 free PSA, 60, 72–75, 98, 301
 half life, 173
 isoforms, 31, 72–74
 pro PSA, 33, 60, 72, 73
 test, 4–8, 25, 26, 29, 72, 85, 94, 300–301, 327–332, 334
 velocity (PSA v), 23, 26–27, 60, 71, 89, 227, 228, 301, 313
 Prostate-specific membrane antigen (PSMA), 229, 264, 267
 PSMA. *See* Prostate-specific membrane antigen (PSMA)

Q

Quality of life (QoL), 19, 28, 30, 32, 81, 87, 90, 108–109, 124, 137–139, 147, 148, 158, 167, 201, 217, 221, 234, 242, 243, 246–247, 254, 310, 311, 316, 317, 328, 331–334

R

Radiation safety, 120
 Radiation therapy oncology group (RTOG) trials
 RTOG 85-31, 160, 163, 177, 286–289
 RTOG 86-10, 160
 RTOG 92-02, 160, 167
 RTOG 94-08, 164
 RTOG 94-13, 160, 162, 166
 Radiation therapy techniques, 182–183, 185
 Radiolabeled monoclonal antibody, 267
 Radiotherapy, 30, 47, 58, 70, 122, 129, 134, 135, 137, 138, 143–151, 157–168, 178, 180, 192, 202, 215, 225, 227, 230–234, 244–246, 291, 306–308
 Radium, 113, 268
 Recurrence, 9, 45, 50, 51, 57, 58, 60, 87, 108, 114, 122, 124–125, 136, 139, 144, 145, 146, 149–151, 158, 159, 161, 164, 173–175, 176, 177–181, 195, 197–198, 202–206, 215, 219, 225–234, 245, 265, 288, 290, 291, 293, 294, 305–307, 308, 309, 312–316
 Retropubic approach, 93, 114
 Risk factors, 3, 8–10, 31, 32, 57, 62, 70, 74, 90, 178, 289, 290, 300, 305, 312, 313
 Roach formula, 166, 314
 Robot, 94, 199, 217, 332
 assisted radical prostatectomy, 105–110
 clinical outcome, 107–108
 complications, 109
 sexual function, 109
 surgical technique, 106–107
 urinary function, 108–109
 RTOG trials. *See* Radiation therapy oncology group (RTOG) trials

S

- Salvage
 brachytherapy, 124, 232–233
 cryosurgical ablation, 233, 315
 HIFU, 202–203, 205–206, 233
 hormonal therapy, 231–232
 radiotherapy, 174, 178–181, 184–185, 228, 230–232, 234, 291
 radiotherapy with adjuvant radiation therapy (ART), 184–185
 surgery, 124–125, 202–203, 208, 232
- Sarcosine, 75, 76
- SBRT. *See* Stereotactic body radiotherapy (SBRT)
- Screening, 4, 13, 14, 18, 25–34, 56, 70, 71, 85–86, 88, 158, 191, 195, 204, 207, 299–318, 328, 330–332
 program, 4, 27, 28
- Selenium, 9, 10, 15–16
- Side effects, 19, 21, 27, 28, 34, 86, 90, 96, 109, 120, 158, 162, 167, 168, 174, 183–185, 200, 203, 205, 225, 229–231, 233, 234, 242, 243, 245–247, 254, 256, 268, 313, 316, 318, 330–332
- Single nucleotide polymorphisms (SNPs), 8
- Sipuleucel T, 263, 264, 266, 271, 318
- SNPs. *See* Single nucleotide polymorphisms (SNPs)
- South Western Oncology Group (SWOG) trial, 176, 183, 184, 231, 234, 308, 314
- Staging, 48–50, 77, 229, 301–303
- Stereotactic body radiotherapy (SBRT), 150–151
- Stranded seeds, 118
- Sunitinib, 269
- Surgery, 94–98, 106–107, 109–110, 202, 214–215, 226–232, 234, 245
- Surgical
 castration, 158, 241, 242, 244, 310–312, 330
- SWOG trial. *See* South Western Oncology Group (SWOG) trial

T

- TAK-700, 256, 268
- Tasquinimod, 266, 269
- Taxanes, 166, 255, 262, 318
- Tissue markers, 56–59
- TNM classification. *See* Tumor node metastasis (TNM) classification
- Transmembrane protease, serine 2 (TMPRSS2), 57, 62–63, 75
 TMPRSS2-ERG (fusion gene), 57, 62–63, 75–76, 258, 268
- Transurethral resection of the prostate (TURP), 94, 97, 114, 115, 123, 131, 138, 200, 244, 307, 330
- Treatment planning, 115–117, 131–135, 176, 183, 184, 193–195, 197–198, 216
- Tumor node metastasis (TNM) classification, 69, 76–77, 160, 168, 279, 300
- TURP. *See* Transurethral resection of the prostate (TURP)

U

- Urinary function, 98, 108–109, 217, 308

V

- Vaccines, 261, 263–265, 318
- Vitamin E, 9, 10, 15–17

Z

- Zoledronic acid, 270, 318